Last reviewed · How we verify
Everolimus Eluting Coronary Stent System — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Everolimus Eluting Coronary Stent System (Everolimus Eluting Coronary Stent System) — Spanish Society of Cardiology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Everolimus Eluting Coronary Stent System TARGET | Everolimus Eluting Coronary Stent System | Spanish Society of Cardiology | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Everolimus Eluting Coronary Stent System CI watch — RSS
- Everolimus Eluting Coronary Stent System CI watch — Atom
- Everolimus Eluting Coronary Stent System CI watch — JSON
- Everolimus Eluting Coronary Stent System alone — RSS
Cite this brief
Drug Landscape (2026). Everolimus Eluting Coronary Stent System — Competitive Intelligence Brief. https://druglandscape.com/ci/everolimus-eluting-coronary-stent-system. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab